Adalimumab — CPB 0655 | AETNA Coverage Update

Aetna modified CPB 0655 covering adalimumab and its biosimilars, effective January 9, 2026. Here's what billing teams need to know before submitting another prior authorization.

Aetna, a CVS Health company, updated its adalimumab coverage policy to govern 11 distinct adalimumab products — including Humira and 10 biosimilars — billed under HCPCS codes J0139, Q5140, Q5141, Q5142, Q5143, Q5144, and Q5145. The modified CPB 0655 Aetna policy tightens prescriber specialty requirements and adds biomarker testing criteria that directly affect whether your prior authorization gets approved or denied. If your practice bills adalimumab for rheumatology, dermatology, gastroenterology, or ophthalmology, this change affects your workflow now.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Adalimumab — CPB 0655
Policy Code	CPB 0655
Change Type	Modified
Effective Date	January 9, 2026
Impact Level	High
Specialties Affected	Rheumatology, Dermatology, Gastroenterology, Ophthalmology, Oncology/Hematology
Key Action	Audit active adalimumab prior authorizations against new biomarker and specialty prescriber criteria before resubmitting

---

Aetna Adalimumab Coverage Criteria and Medical Necessity Requirements 2026

The updated CPB 0655 Aetna coverage policy sets strict prescriber specialty requirements. The prescribing physician must match the indication. A rheumatologist must prescribe for rheumatoid arthritis (RA), ankylosing spondylitis, non-radiographic axial spondyloarthritis, and Behcet's disease. Dermatologists cover plaque psoriasis and pyoderma gangrenosum. Gastroenterologists cover Crohn's disease and ulcerative colitis. Psoriatic arthritis and hidradenitis suppurativa require either a rheumatologist or dermatologist.

For uveitis, either an ophthalmologist or rheumatologist satisfies the prescriber requirement. For immune checkpoint inhibitor-related toxicity, an oncologist, hematologist, or rheumatologist may prescribe.

This matters because a prescription written outside the required specialty triggers a medical necessity denial. It doesn't matter how well the clinical criteria are met. A PCP or internist prescribing adalimumab for RA — even when clinically appropriate — won't satisfy this requirement. You need a qualifying specialist on the order or in documented consultation.

Rheumatoid Arthritis: The Biomarker and Step Therapy Requirements

For RA, Aetna's updated coverage policy creates two paths to approval. The first path applies to members who received a biologic or targeted synthetic drug — such as Rinvoq or Xeljanz — within the past 120 days. Those members qualify without additional step therapy.

The second path is more complex. Aetna requires documented biomarker testing. The member must have tested positive for rheumatoid factor (RF, billed as CPT 86430 or 86431) or anti-CCP (CPT 86200). Alternatively, the member must have been tested for all three: RF, anti-CCP, and either CRP (CPT 86140 or 86141) or ESR (CPT 85651 or 85652). The distinction matters — a negative panel still satisfies criteria if all tests were run.

On top of biomarker testing, Aetna requires documented step therapy failure. The member must have failed a 3-month trial of methotrexate (MTX) at a maximum titrated dose of at least 15 mg per week. That failure can be through inadequate response, intolerable adverse events, or a documented contraindication to MTX combination partners like hydroxychloroquine or sulfasalazine.

The real issue here is documentation. Aetna will look for every piece of this in the prior authorization submission. A chart note that says "tried MTX, didn't work" is not enough. You need the dose, the duration, and the response — or the contraindication — spelled out explicitly.

Tuberculosis Screening: Required Before Approval

Before adalimumab can be approved for most indications, Aetna requires documented TB screening. Your team should be capturing CPT 86480 or 86481 (IGRA-based TB tests) or CPT 86580 (TB skin test) in the patient record. Missing TB screening documentation is a fast path to a claim denial on the prior auth review.

Chest X-ray codes — CPT 71045, 71046, 71047, and 71048 — are also referenced in CPB 0655 and may be required in the TB workup. Make sure the radiology report is in the authorization package when relevant.

---

Aetna Adalimumab Exclusions and Non-Covered Indications

Aetna does not cover adalimumab when it is prescribed outside the approved specialty and indication pairings listed in CPB 0655. A dermatologist prescribing adalimumab for Crohn's disease does not satisfy the specialty requirement — that indication requires a gastroenterologist.

Adalimumab prescribed without documented biomarker testing for RA — where testing is required — is not medically necessary under this policy. Aetna will not approve the prior authorization without the lab documentation. You can't substitute clinical notes for missing CPT 86200, 86430, or 86431 results.

Step therapy bypasses without documentation of intolerance, inadequate response, or contraindication also fall outside the coverage policy. The policy is clear that moderate-to-high disease activity can satisfy step therapy requirements in some circumstances — but that determination must come from a qualifying specialist and be reflected in the chart.

---

Coverage Indications at a Glance

---

Aetna Adalimumab Billing Guidelines and Action Items 2026

The effective date of January 9, 2026 means this policy is already in force. If you haven't audited your adalimumab prior authorization workflow against these criteria, do it now.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Adalimumab Under CPB 0655

HCPCS Codes — Adalimumab Products

CPT Codes — Diagnostic and Supporting Tests

These codes document the biomarker testing, TB screening, and administration that Aetna requires as part of the medical necessity determination.

Biomarker Testing

Tuberculosis Screening

Code	Description Copy
86480	TB test, cell mediated immunity; gamma interferon
86481	TB test, cell mediated immunity; enumeration of gamma interferon
86580	Skin test; tuberculosis, intradermal

Chest Radiography (TB Workup)

Drug Administration

Code	Description Copy
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular

HCPCS Codes — Related Drugs Referenced in Policy

---